BUNAVAIL

This brand name is authorized in United States.

Active ingredients

The drug BUNAVAIL contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII 56W8MW3EN1 - BUPRENORPHINE HYDROCHLORIDE
 

Buprenorphine is an opioid partial agonist/antagonist which attaches itself to the μ (mu) and κ (kappa) receptors of the brain. Its activity in opioid maintenance treatment is attributed to its slowly reversible link with the μ receptors which, over a prolonged period, minimises the need of illicit opioids for patients with opioid dependence.

 
Read more about Buprenorphine
2
UNII 5Q187997EE - NALOXONE HYDROCHLORIDE DIHYDRATE
 

Naloxone hydrochloride, a semisynthetic morphine derivative (N-allyl-nor-oxymorphone), is a specific opioid antagonist that acts competitively at opioid receptors. It reveals very high affinity for the opioid receptor sites and therefore displaces both opioid agonists and partial antagonists, such as pentazocine, for example, but also nalorphine.

 
Read more about Naloxone

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
US FDA, National Drug Code 59385-012, 59385-014, 59385-016

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.